• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Future Pak Submits Proposals to Acquire Theratechnologies Inc., Offering up to $255 Million in Total Value

    4/11/25 9:57:00 AM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $THTX alert in real time by email

    Future Pak, LLC ("Future Pak") today announced that it has submitted two formal proposals since January to acquire all outstanding shares of common stock of Theratechnologies Inc. ("Theratechnologies") (NASDAQ:THTX). The most recent proposal, which remains open for consideration by Theratechnologies and its Board of Directors, offers a cash consideration of $3.51 to $4.50 per share.

    The proposal represents a total enterprise value of up to $255 million, comprising:

    • $205 million in cash at closing, and
    • Up to $50 million in contingent value right (CVR) payments, including:
      • 50% of the annual EGRIFTA® franchise gross profit (defined as net sales minus cost of goods, per U.S. GAAP) above $30 million annually for three years post-closing.
      • A $10 million one-time milestone payment if cumulative EGRIFTA gross profit exceeds $125 million over the same three-year period.

    This offer implies a 164% to 238% premium to Theratechnologies' closing stock price of $1.33 as of April 10, 2025.

    "To move this process forward efficiently and deliver compelling value to Theratechnologies' shareholders, we have submitted multiple offers outlining a flexible and attractive framework," said Nirav Patel, Chief Growth Officer at Future Pak. "We believe this proposal provides significant upside and a solid foundation for constructive dialogue, with the goal of achieving a mutually beneficial transaction."

    Despite repeated outreach and the submission of two detailed proposals—each offering a premium of more than 100% over Theratechnologies' trading price—Future Pak has received minimal engagement from the company to date.

    Future Pak confirms that the transaction would not be subject to a financing contingency and has the full support of its strategic financial partner, Colbeck Capital Management.

    Future Pak has engaged Bourne Partners Securities LLC as financial advisor and Honigman LLP as legal advisor. Given access to standard due diligence materials, Future Pak believes it could reach a definitive agreement and announce a transaction within four to six weeks.

    By publicly disclosing its interest, Future Pak hopes to encourage Theratechnologies shareholders to engage with the proposal and ensure that the Board fulfills its duty to pursue the highest value outcome available.

    About Future Pak

    Founded in 1977 and headquartered in Wixom, Michigan, Future Pak is a privately held contract manufacturer and packager of pharmaceutical and nutraceutical products. The company operates across retail, specialty, and institutional markets, leveraging its robust infrastructure and partner network to deliver quality-first, patient-centric solutions.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250411477925/en/

    Investors and media may contact [email protected].

    Get the next $THTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $THTX

    DatePrice TargetRatingAnalyst
    11/17/2022$9.00Overweight
    Cantor Fitzgerald
    7/29/2021$8.00 → $3.00Buy → Hold
    Canaccord Genuity
    More analyst ratings

    $THTX
    SEC Filings

    View All

    SEC Form 6-K filed by Theratechnologies Inc.

    6-K - Theratechnologies Inc. (0001512717) (Filer)

    8/18/25 8:15:52 AM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Theratechnologies Inc.

    6-K - Theratechnologies Inc. (0001512717) (Filer)

    8/18/25 7:52:04 AM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Theratechnologies Inc.

    SCHEDULE 13G/A - Theratechnologies Inc. (0001512717) (Subject)

    8/5/25 3:08:52 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $THTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Theratechnologies Announces Filing of Special Meeting Materials and Receipt of Interim Order in Relation to its Acquisition by CB Biotechnology, an Affiliate of Future Pak

    Shareholders stand to receive a significant and attractive cash premium, as the purchase price of US$3.01, with a contingent value right for potential additional aggregate payments of up to US$1.19 per share, represents a compelling premium of 216% to the closing price on the Nasdaq on April 10, 2025, the date prior to the announcement of Future Pak's initial non-binding proposal.Board unanimously recommends shareholders vote "FOR" the Arrangement.Shareholders are encouraged to review the circular carefully and submit their proxies in advance of the proxy voting deadline of 10:00 a.m. (Eastern time) on September 10, 2025.Visit www.theratech.com for more information.Questions or require votin

    8/18/25 7:30:00 AM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theratechnologies Reports Financial Results for the Second Quarter 2025

    Q2 2025 total revenue of $17.7 million, and $36.8 million for the first six months of Fiscal 2025Positive Adjusted EBITDA1 for the fifth straight quarterSubsequent to quarter end, Theratechnologies entered into a definitive agreement to be acquired by an affiliate of Future Pak MONTREAL, July 09, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today reported business highlights and financial results for the second quarter 2025, ended May 31, 2025. All figures are in U.S. dollars unless otherwise stated. "Demand for EGRIFTA SV® remains very strong and we are witnessing

    7/9/25 7:30:00 AM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theratechnologies to Announce Second Quarter 2025 Financial Results

    MONTREAL, July 03, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today announced the Company will report financial results for its second quarter 2025 ended May 31 on Wednesday, July 9, 2025. Given the announcement of July 2, 2025, concerning the acquisition of the Company, a conference call will not be held. About Theratechnologies Theratechnologies (TSX:TH) (NASDAQ:THTX) is a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care. Further information about Theratechnologies is availabl

    7/3/25 5:30:00 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Theratechnologies with a new price target

    Cantor Fitzgerald initiated coverage of Theratechnologies with a rating of Overweight and set a new price target of $9.00

    11/17/22 7:27:25 AM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theratechnologies downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Theratechnologies from Buy to Hold and set a new price target of $3.00 from $8.00 previously

    7/29/21 9:53:58 AM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity reiterated coverage on Theratechnologies with a new price target

    Canaccord Genuity reiterated coverage of Theratechnologies with a rating of Buy and set a new price target of $8.00 from $7.00 previously

    4/19/21 9:31:33 AM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THTX
    Financials

    Live finance-specific insights

    View All

    Theratechnologies Reports Financial Results for the Second Quarter 2025

    Q2 2025 total revenue of $17.7 million, and $36.8 million for the first six months of Fiscal 2025Positive Adjusted EBITDA1 for the fifth straight quarterSubsequent to quarter end, Theratechnologies entered into a definitive agreement to be acquired by an affiliate of Future Pak MONTREAL, July 09, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today reported business highlights and financial results for the second quarter 2025, ended May 31, 2025. All figures are in U.S. dollars unless otherwise stated. "Demand for EGRIFTA SV® remains very strong and we are witnessing

    7/9/25 7:30:00 AM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theratechnologies to Announce Second Quarter 2025 Financial Results

    MONTREAL, July 03, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today announced the Company will report financial results for its second quarter 2025 ended May 31 on Wednesday, July 9, 2025. Given the announcement of July 2, 2025, concerning the acquisition of the Company, a conference call will not be held. About Theratechnologies Theratechnologies (TSX:TH) (NASDAQ:THTX) is a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care. Further information about Theratechnologies is availabl

    7/3/25 5:30:00 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak

    Offer of US$3.01 in cash plus one contingent value right for potential additional aggregate payments of up to US$1.19 per shareUpfront and total potential cash consideration represent respectively a 126% and 216% premium to Nasdaq closing price on date prior to announcement of Future Pak's initial non-binding proposalTransaction with Future Pak represents culmination of sale process whereby Theratechnologies solicited interest from a number of potential counterpartiesBoard unanimously recommends that shareholders approve the transaction MONTREAL, July 02, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage bio

    7/2/25 10:11:00 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THTX
    Leadership Updates

    Live Leadership Updates

    View All

    Theratechnologies Appoints Elina Tea to its Board of Directors

    MONTREAL, April 05, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Elina Tea, Chief Financial Officer at GLS North America, to its Board of Directors and as a member of the Company's Audit Committee. Ms. Tea will be Investissement Québec's designee pursuant to its investor rights agreement with the Company. "Elina Tea's extensive experience in finance, corporate strategy, and investor relations makes her a valuable addition to our Board of Directors," said Dawn Svoronos, Chair of the Board o

    4/5/24 11:00:00 AM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theratechnologies Appoints Jordan Zwick to its Board of Directors

    MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Jordan Zwick, Chief Business Officer at Mirador Therapeutics Inc., to its Board of Directors and as a member of the Company's Audit Committee. "We welcome Jordan Zwick to the Board as an important addition to our esteemed group of advisors," said Dawn Svoronos, Chair of the Board of Directors at Theratechnologies. "With his extensive experience in the U.S. biotech and pharmaceutical industry, coupled with expertise in global

    3/21/24 8:00:00 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau

    MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Mr. Alain Trudeau has resigned from the Board of Directors of Theratechnologies and as a member of its Audit Committee, effective immediately. "I want to thank Alain for his contributions to Theratechnologies as a director since joining the Company in October 2020 and for completing the annual review for the 2023 fiscal year", said Dawn Svoronos, Chair of the Board at Theratechnologies. "Alain was the current Chair of the Audit Committee

    2/29/24 4:34:00 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Theratechnologies Inc.

    SC 13G - Theratechnologies Inc. (0001512717) (Subject)

    2/14/24 4:51:41 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Theratechnologies Inc. (Amendment)

    SC 13G/A - Theratechnologies Inc. (0001512717) (Subject)

    2/7/24 6:55:18 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Theratechnologies Inc.

    SC 13D - Theratechnologies Inc. (0001512717) (Subject)

    11/28/23 4:52:43 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care